VolitionRx Limited Takes a Significant Step with Nu.Q® Cancer Assays
VolitionRx Limited (NYSE AMERICAN: VNRX), a leading epigenetics company, has announced an important development regarding its Nu.Q® Cancer assays. The company is currently in the process of preparing a reimbursement submission aimed at securing coverage through governmental healthcare systems. This ambitious plan is supported by the renowned Hospices Civils de Lyon (HCL), which is recognized as France's second largest university hospital system.
Aiming for Routine Clinical Use
In partnership with HCL, VolitionRx is working diligently to ensure that these innovative cancer assays can be integrated into the routine clinical practices within hospitals. Professor Léa Payen from HCL highlighted her enthusiasm for the opportunity to include Nu.Q® Cancer assays in standard lung cancer management.
Commitment to Patient Care
Professor Payen remarked that the tests could significantly enhance the way lung cancer patients are monitored and treated. The evidence gathered from using the Nu.Q® assays demonstrates their potential in providing crucial insights at the time of Non Small Cell Lung Cancer diagnosis. This could lead to improved survival outcomes and better identification of candidates for curative options.
Timelines and Importance of Reimbursement
Frederic Wuilque, Vice President of Global Products at Volition, noted the strategic importance of submitting their reimbursement dossier before the deadline set for the end of the current quarter. This submission falls within a framework designed for reviewing innovative medical procedures, which emphasizes the critical timeline for eligibility determinations.
An Expansive Opportunity Ahead
With around 50,000 new lung cancer cases diagnosed annually in France, the scope for employing Nu.Q® assays in patient management is enormous. Beyond France, VolitionRx is exploring engagement with hospital networks in other countries and is considering potential licensing agreements to broaden access to their technology globally.
Volition's Mission and Future Vision
Chief Commercial Officer, Mr. Gael Forterre, expressed gratitude for the partnership with HCL, emphasizing that achieving reimbursement is crucial for introducing their cancer test into clinical settings. He stated that this step aligns perfectly with Volition's mission to utilize their groundbreaking tests to improve patient outcomes and expand the range of available precision medicine tools.
Future Availability of Nu.Q®
Upon successful reimbursement, the organization envisions that Nu.Q® Cancer assays will be widely used in France by the fourth quarter of the next year, marking a significant milestone in the company’s journey. Such a development not only represents a leap in cancer diagnostics but also enhances opportunities for patients globally.
Innovative Procedures and Medical Advancements
The reimbursement process falls under the Innovative Procedures Outside the Nomenclature (RIHN), which aims at early backing of new methodologies in healthcare. The approach allows for temporary support while crucial data is collected for the evaluation of these innovative medical biology procedures by health authorities.
Partnering for Quality Healthcare
With its galaxy of capabilities, including state-of-the-art facilities and collaborations with research institutes, HCL plays a pivotal role in advancing medical strategies. Their concerted efforts in research and clinical practice are set to sharpen the focus on delivering high-quality healthcare solutions to patients.
About VolitionRx Limited
Volition, dedicated to advancing epigenetic science, aims to save lives and enhance quality of life through early disease detection. The company focuses on developing straightforward, cost-effective blood tests to monitor various diseases, including cancer.
Through relentless R&D efforts, VolitionRx is paving the way for improved monitoring and detection methods, promising a brighter outlook for patients navigating serious health challenges.
Frequently Asked Questions
What is the purpose of the Nu.Q® Cancer assays?
The Nu.Q® Cancer assays aim to provide an innovative tool for monitoring and managing lung cancer, helping healthcare professionals make informed decisions based on patient-specific data.
Who supports VolitionRx in their reimbursement submission?
The submission is significantly supported by Hospices Civils de Lyon (HCL), a key partner and major university hospital system in France.
What are the expected timelines for the reimbursement process?
VolitionRx anticipates submitting its reimbursement dossier shortly, seeking classification and eligibility determination which should take around five months.
Why is reimbursement crucial for VolitionRx?
Reimbursement is a critical milestone as it facilitates the transition from innovation to clinical practice, enabling broader access to crucial diagnostic tests for lung cancer.
How does VolitionRx ensure the quality of its assays?
VolitionRx collaborates with leading healthcare institutions and relies on rigorous scientific and clinical evidence to develop and validate the effectiveness of its assays.
